MOMETASONE ZENTIVA 50 micrograms/dose, suspension for spraying nasal bottle, 16 g
Active ingredients: Mometasone furoate, Mometasone furoate monohydrate
Commercialized according to BDPMDispensing in France: Prescription only
Suspension for sprayingbottle, 16 gnasale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- MOMETASONE ZENTIVA 50 microgrammes/dose, suspension pour pulvérisation nasale
- Pharmaceutical form
- suspension pour pulvérisation
- Route of administration
- nasale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) de 16 g (120 doses), avec pompe doseuse et applicateur nasal
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- 30 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 5 May 2020
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63491598CIP73015129CIP133400930151297Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FUROATE DE MOMÉTASONEsuspension | 50 microgrammes · une dose délivrée | FT |
| FUROATE DE MOMÉTASONE MONOHYDRATÉsuspension | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.